angiogenesis ͉ endothelium ͉ adenovirus ͉ tumor ͉ stem
ndothelial cells (ECs) are not only conduits for delivering oxygen and nutrients but they also provide a permissive niche for the maintenance of organ-specific tissues and tumor cells (1) . Within the bone marrow (BM) hematopoietic stem cells interact with sinusoidal ECs and undergo self-renewal or differentiation (1, 2) . ECs contribute to self-renewal of neuronal stem cells (3) and promote the growth of leukemic cells (4) and gliomas (5) . However, hurdles associated with cultivating functional primary ECs (PECs) in long-term cultures have hindered identification of the molecular pathways involved in the interaction of PECs with stem and tumor cells.
Maintenance of PECs in vitro requires utilization of enriched EC growth medium that is supplemented with serum, proangiogenic factors, including VEGF-A, FGF-2, EGF, IGF, and EC growth supplement. Notably, deprivation of PECs for few hours from these growth factors results in a rapid cell death. Therefore, the use of PECs as feeder cells needs to be performed in the presence of EC growth medium, which artificially influences the growth of cocultivated stem and tumor cells, providing a major confounding variable in such studies.
To overcome these hurdles, PECs have been immortalized with hTERT or SV40 large T and polyoma middle T oncogenes. However, activation of proliferative phospho MAPK (pMAPK) signaling pathways in these cell lines has resulted in generation of dysregulated ECs that are either serum-dependent or have acquired transformed phenotypes atypical of PECs. Furthermore, because of a high metabolic rate, immortalized PECs deprive the cocultured stem and tumor cells of nutrients, resulting in cell death.
In search for factors that can support long-term survival of PECs without inducing transformation, we have discovered that the adenoviral (Ad) E4ORF1 gene, when introduced into PECs (E4ORF1 ؉ ECs), results in generation of a long-lasting angiogenic state, in which the majority of the provascular functions are preserved. The angiogenic repertoire of E4ORF1 ؉ ECs is similar to early passaged PECs, thereby providing a permissive experimental platform to investigate organogenesis and tumorigenesis.
The gene products encoded by early region 4 (E4) of adenovirus are essential for virus replication, modulating cell cycle, apoptosis, and cell signaling (6) . We have shown that the Ad-E4 gene complex maintains angiogenic properties of PECs, by modulating the migration and apoptosis of PECs (7) . Ad E4 products promote PEC survival via increasing Src kinase and PI3-kinase phosphorylation, and by reducing caspase-3 activity (8) . However, the identity of the specific genes transcribed within the E4 gene complex that regulates angiogenesis up to now has remained elusive.
Indeed, Ad E4 mRNA contains 7 ORFs, suggesting that E4 encodes at least 6 gene products (E4ORF1-E4ORF6/7). Among the known E4 ORFs, E4ORF1 primarily affects survival but not cell proliferation (9, 10) . Therefore, we hypothesized that E4ORF1 may modulate survival in ECs without promoting oncogenic transformation.
Here, we show that E4ORF1 introduction into the human PECs increases the survival of PECs in serum/cytokine-free culture conditions without enforcing cell proliferation. The prosurvival effect of E4ORF1 is mediated through Akt-PI3-kinase-mTOR and NF-B activation without switching on the MAPK pathway, thereby maintaining the angiogenic functions of PECs, including neovascularization in vivo. E4ORF1
؉ ECs also provide a permissive microenvironment for the growth of leukemic and embryonal carcinoma cells. As such, E4ORF1 allows for generation of durable PECs that can be maintained long term as intact monolayers, even under minimal growth medium conditions, thereby enabling interrogation of the role of PECs in organogenesis and tumorigenesis.
Results
Ad E4ORF1 Gene Product Promotes Survival of PECs. The E4 region of the Ad vectors contains 7 ORFs (E4ORF1, E4ORF2, E4ORF3, E4ORF4, E4ORF3/4, E4ORF6, and E4ORF6/7), encoding 6 distinct polypeptides (6) . We showed that adenovirus E4 ϩ vectors, expressing the full complement of E4 gene products, promote PEC survival in the absence of angiogenic factors and serum (7, 8) . However, it was unclear which of the 6 E4ORF gene products conferred this proangiogenic phenotype to PECs. To identify the specific Ad E4ORF that selectively promotes neoangiogenesis, human PECs were infected in serum/cytokine-free medium with Ad vectors carrying various E4ORF sequence deletions, including a panel of E4 deletion mutants selectively expressing the gene products of E4ORF1, E4ORF4, E4ORF6, or a combination of E4ORF3,4,6,6/7.
An increase in the survival of PECs was observed only in cells infected with AdE4ORF1 (which expresses only ORF1) ( Fig. 1 A  and B) . In contrast, E4ORF1-deleted adenovirus vectors, including AdE4ORF3,4,6,6/7, AdE4ORF4 (which expresses only E4ORF4), or AdE4ORF6 (which expresses only E4ORF6) did not improve PEC survival in serum/cytokine-free conditions. Thus, among the E4ORFs only E4ORF1 plays a central role in the regulation of PEC survival.
To rule out involvement of the other Ad-encoded proteins, we generated a lentivirus construct that expresses only E4ORF1. Primary ECs [human umbilical vein ECs (HUVECs)] were transduced with lenti-E4ORF1 (E4ORF1 ؉ ECs) or control lenti-GFP (E4ORF1 Ϫ ECs) viruses. Infection of PECs with lenti-E4ORF1 phenocopied the proangiogenic effect conferred by AdE4ORF1, increasing the survival of E4ORF1
؉ ECs in serum/cytokine-free medium, compared with infection with lenti-GFP or noninfected PECs ( Fig. 1 C and D) . Transduction efficiency of PECs was nearly 100%, as measured by GFP expression in lenti-GFP-infected cells. A similar effect of lenti-E4ORF1 was also observed in lymphatic PECs (Fig. 1E) . Hence, the expression of E4ORF1 by introduction of lenti-E4ORF1 replicated the effect of Ad E4 ϩ vectors on prolongation of PEC survival, demonstrating that E4ORF1 mediates the prosurvival effect of the Ad E4 gene in PECs.
To verify the capacity of E4ORF1 to selectively promote the outgrowth of organ-specific PECs, crude populations of fresh cord blood or enzymatically digested human testicular cells and BM were infected with lenti-E4ORF1. As compared with noninfected cultures, which were overgrown with stromal cells, lenti-E4ORF1 cultures supported the selective outgrowth of PECs (Fig. 1F) . The PECs were highly pure, grew in a contacted inhibited manner, and expressed the typical markers of PECs, including, CD34, von Willebrand factor (VWF), VE-cadherin, and CD31 [supporting information (SI) Fig. S1 ]. These results indicate that the E4ORF1 gene product could be used for purification of organ-specific ECs by conferring a prosurvival advantage to PECs.
Akt Is Chronically Phosphorylated in E4ORF1 ؉ ECs. Sustained phosphorylation of Akt is critical for the prolongation of survival of PECs that carry AdE4ORF137 vectors (8) , which express all 6 E4ORF gene products. To test whether E4ORF1 is responsible for phosphorylation of Akt in PECs (HUVECs) transduced with the AdE4ORF137 vector, siRNA against E4ORF1 was used to inhibit expression of the E4ORF gene. Infection of the PECs with either AdE4ORF137 or AdE4ORF1, but not the AdE4ORF3,4,6,6/7 vector (which lacks E4ORF1 expression), induced phosphorylation of Akt on Ser-473, with total Akt remaining constant ( Fig. 2 A and  B) . However, pretreatment of PECs with siRNA against E4ORF1 inhibited AdE4ORF137 vector-induced pAkt activation as compared with the PECs transfected with either fluorescein-labeled control siRNA or siRNA against E4ORF6 (which expresses only E4ORF6). Moreover, in serum/cytokine-free conditions, infection of PECs with the lenti-E4ORF1 vector also increased Akt phos- phorylation at Ser-473 (Fig. 2C) , as compared with control or to infection with lenti-GFP, indicating that Akt activation is E4ORF1-specific.
To test whether transduction with lenti-E4ORF1 prolongs PEC survival through PI3K, mTOR, or NF-B signaling, we treated lenti-E4ORF1-infected ECs (E4ORF1 ϩ ECs) with rapamycin, an inhibitor of the mTOR signaling, wortmannin, an inhibitor of PI3-kinase signaling or caffeic acid phenethylester (CAPE), a NK-B inhibitor. Wortmannin significantly suppressed the prosurvival effect of E4ORF1, suggesting that PI3-kinase activation of Akt is the primary mechanism by which E4ORF1 supports survival of ECs (Fig. 2D) . However, either rapamycin or CAPE only partially inhibited the survival of E4ORF1 ؉ ECs, whereas the combination of rapamycin and CAPE completely blocked the survival of E4ORF1 ؉ ECs under serum/cytokine-free conditions (Fig. 2D ). These data suggest that E4ORF1-mediated activation of the PI3-kinase-Akt pathway promotes long-term survival of PECs through recruitment of both mTOR and NF-B signaling pathways.
To determine whether E4ORF1 might also activate MAPK, E4ORF1 ؉ ECs were treated with MAPK inhibitors PD98059 (PD for ERK), SB203580 (SB for p38-MAPK), respectively. Neither SB nor PD had significant effects on the survival of E4ORF1 ؉ ECs (Fig. 2E) . Indeed, in contrast to the sustained pAkt activation observed in E4ORF1 ؉ ECs, there was no baseline activation of MAPK in E4ORF1
؉ ECs as seen in control E4ORF1 Ϫ ECs (Fig.  2F) . Therefore, E4ORF1-mediated prolongation of PEC survival involves Akt activation without stimulating the MAPK pathway. However, stimulation with VEGF-A resulted in a comparable activation of pMAPK observed in E4ORF1 ؉ ECs or control (E4ORF1 Ϫ ECs). These data indicate that E4ORF1 ؉ ECs maintained their responsiveness to VEGF-A. 
E4ORF1
؉ ECs (HUVECs) express FGF receptor 1 (FGF-R1) (Table S1 ). E4ORF1
ϩ ECs have increased FGF-2 protein expression, when compared with naïve PECs or PECs transduced with E4ORF1 null vectors ( Fig. 3 A and B) . FGF-2 knockdown partially blocked lenti-E4ORF1 increase in FGF-2 or survival of PECs ( Fig.  3 C and D) . Knockdown of FGF-2 by siRNA was confirmed by Western blot analysis and suppressed E4ORF1-induced FGF-2 protein expression (Fig. 3B) .
We also demonstrated that a specific mAb to human FGF-R1 (clone H7), selectively blocked the proliferation of E4ORF1 ؉ ECs afforded by exogenous FGF-2 ( Fig. 3E) . However, inhibition of E4ORF1 ؉ ECs by mAb to FGF-R1, in the absence of exogenous FGF-2, had no major effect on the survival of the ECs, suggesting that intrakine activation of FGF-2/FGF-R1 may play a role in supporting the survival of E4ORF1
؉ ECs (Fig. 3E ). Indeed, although SU5402 (an inhibitor of FGF-R1 tyrosine kinase activity) blocked expansion of recombinant FGF (rFGF) -treated E4ORF1 ϩ ECs, the VEGF-A receptor inhibitor (SU5416) did not significantly affect the survival of E4ORF1 ϩ ECs (Fig. S2) . These data suggest that E4ORF1 may exert its prosurvival effect in part through activation of the FGF-2/FGF-R1 complex.
To confirm these results, we found that in the absence of any serum or cytokines, E4ORF1 ϩ ECs (HUVECs) survive for several weeks without proliferation, maintaining their contact-inhibited status (Fig. 3F) . By contrast, in serum/cytokine-free conditions, E4ORF1 Ϫ ECs underwent apoptosis. Addition of rFGF-2 to serum/cytokine-free cultures of E4ORF1 ϩ ECs augmented proliferation of these cells. Although initially rFGF-2 also supported the survival of E4ORF1 Ϫ ECs, such cells became progressively apoptotic. Addition of recombinant VEGF-A (rVEGF-A) alone or in conjunction with rFGF-2 also increased the expansion of E4ORF1 ϩ ECs. These data suggest that E4ORF1
ϩ ECs retain their responsiveness to VEGF-A and FGF-2 and that, under serum/ cytokine-free conditions, E4ORF1-mediated activation of pAkt supports the survival of E4ORF1 ϩ ECs.
E4ORF1 Maintains the Angiogenic Properties of PECs. Similar to FGF-2 induced migration, we found that AdE4ORF1 ϩ ECs have retained their capacity to migrate in a wound assay in serum/cytokine-free conditions (Fig. S3) . In contrast, uninfected E4ORF1 Ϫ ECs in serum/cytokine-free medium were unable to migrate, instead undergoing apoptosis. PECs infected with either AdE4ORF1 or lenti-E4ORF1 also maintained their ability to form tubes in serum/ cytokine-free conditions, whereas naïve PECs or AdE4ORF3,4,6,6/ 7-infected ECs (lacking E4ORF1) failed to form stable tubes (Fig.  S3 ). These data indicate that E4ORF1 ϩ ECs maintain their angiogenic potential in vitro.
To determine whether E4ORF1 ϩ ECs (HUVECs) could survive in vivo and assemble into functional neo-vessels, E4ORF1 ϩ ECs and naïve PECs were implanted in the flanks of NOD-SCID mice. Whereas normal PECs were barely detectable 5 days after s.c. injection (Fig. 4A) , E4ORF1 ϩ ECs survived, established vascular foci (Fig. 4B) , and assembled into vascular-type structures containing red blood cells (Fig. 4 C and D) . Immunostaining with speciesspecific antibodies revealed labeling of nests of engrafted human PECs surrounded by adjacent mouse vessels (Fig. 4 E and F) . Consistent with the biochemical profile of E4ORF1 ϩ ECs in vitro, FGF-2 expression was detected in the engrafted tissue (Fig. 4G) . Staining of these sections with a phospho-Akt-specific antibody shows that E4ORF1 ϩ ECs had maintained their Akt activation (Fig. 4H) . These data indicate that after transplantation, E4ORF1 ϩ ECs retained their Akt-dependent neo-angiogenic potential, forming vascular structures without generating tumors. To interrogate the capacity of E4ORF1 ϩ ECs to assemble into functional vessels in the Matrigel implants in the absence of exogenous cytokines, E4ORF1 ϩ ECs (transduced with lenti-E4OFR1) or naïve ECs (labeled with lenti-GFP) were inoculated into the flanks of NOD-SCID mice. After 2 weeks, vascular perfusion labeling was performed to assess functional human-derived GFP ؉ neo-vessels. Similar to naïve PECs (Fig. 5 A and C) , E4ORF1 ϩ ECs (Fig. 5 B  and D) were able to assemble into functional, branching GFP ؉ lectin ؉ neo-vessels connecting to the host vessels ( Fig. 5 C  and D) . The E4ORF1 ϩ ECs also gave rise to long, sprouting GFP ؉ lectin ؉ neovessels (Fig. 5E ). These data suggest that E4ORF1 ϩ ECs maintain their angiogenic repertoire, even in the absence of FGF-2 and VEGF-A supplementation.
E4ORF1 ؉ ECs Form Neo-Vessels in Leukemic Xenografts. To further assess the angiogenic properties of E4ORF1 ϩ ECs in vivo, we comingled human HL60 leukemia cells with E4ORF1 ϩ ECs and inoculated them s.c. in NOD-SCID mice. Whereas normal ECs do not survive within human tumor xenografts (data not shown), the human VE-cadherin ϩ E4ORF1
ϩ ECs not only survived for at least 10 days within the HL60 tumors but also formed vessel-like structures with a lumen (Fig. 5 F and G) . Double labeling for mouse (MECA32) and human endothelium (human VE-cadherin) (Fig.  5G) confirmed not only the species specificity of the antibodies but also revealed formation of E4ORF1 ϩ vessels within the tumor. These data reveal the potency of E4ORF1 to maintain a angiogenic phenotype in ECs in vivo.
E4ORF1 ؉ ECs Support Expansion of Human Leukemic Cells and Em-
bryonal Carcinomas in Serum/Cytokine-Free Conditions. We have shown that angiogenesis is critical for the growth of leukemic HL60 xenografts (4). However, it has been unclear whether PECs in serum/cytokine-free conditions could support the proliferation of HL60 cells. Here, we found that although in serum/cytokine-free conditions HL60 cells underwent apoptosis, E4ORF1 ϩ ECs maintained their physical integrity and supported expansion of HL60 cells (Fig. 5H) . We have demonstrated that ECs support expansion of leukemic cells without the addition of exogenous cytokines or serum. Notably, in the case of HL60 cells, coculture of these cells in the upper chamber of porous Transwells physically separated from E4ORF1 ϩ ECs resulted in failure of the expansion of HL60 (data not shown). However, E4ORF1 ϩ ECs supported the expansion of human embryonal carcinoma cells that were plated in the upper chambers of Transwells. These data suggest that in serum/ cytokine-free conditions, E4ORF1 ϩ ECs could support growth of certain tumors by release of soluble cytokines, in the case of embryonal carcinomas, or perhaps by elaboration of membranebound cytokines, in the case of leukemias. Therefore, E4ORF1 ϩ ECs establish a durable vascular niche, supporting the expansion of leukemias and solid tumors in the absence of any exogenous growth factor and serum and thereby providing a means to address the mechanisms of cellular cross-talk without previously confounding variables, such as the presence of exogenous growth factors or serum.
Discussion
We have exploited the capacity of the Ad E4 gene to activate cell survival signals to identify factors that can preserve long-term PEC integrity. Of the 6 gene products expressed by the Ad E4 gene complex, we have discovered that the E4ORF1 gene product endows PECs with the capacity to survive and preserves their angiogenic potential in the absence of serum or PEC growth supplements. Although naïve PECs underwent apoptosis within 6 h in cytokine/serum-free conditions, E4ORF1 ϩ ECs supported longterm expansion of leukemic cells and embryonal carcinoma cells under serum/cytokine-free conditions, without themselves undergoing apoptosis. E4ORF1 primarily increases the survival of human PECs without promoting MAPK-dependent cell proliferation. Indeed, through tonic stimulation of PI3-kinase-Akt and recruitment of both mTOR and NF-B pathways, E4ORF1 supported the survival of ECs without immortalization and without activation the MAPK pathway. E4ORF1 increased the survival of ECs, in part by maintaining the expression of FGF-2 and activation of the FGF-2/FGF-R1 pathway. E4ORF1 ϩ ECs sustained the angiogenic profile of ECs and assembled into functional neo-vessels in vitro and in vivo and contributed to angiogenesis in leukemic chloromas. VEGF-A activation of E4ORF1 ϩ ECs activated MAPK to the same extent as naïve PECs, suggesting that E4ORF1 ϩ ECs retain functionality of VEGF-A receptors. The selective prosurvival effect of E4ORF1 allowed isolation of pure populations of organ-specific PECs from multiple adult organs. As such, E4ORF1 facilitated isolation of organ-specific ECs. The use of E4ORF1 ϩ ECs will enable the use of minimal media conditions (i.e., exogenous cytokine/serum-free media) in the study of EC-derived signals in regulating normal and cancer homeostasis. The mechanisms by which ECs support organogenesis and tumorigenesis are not known (1, 2, 4, 5) . To date, the use of immortalized ECs lines has manifested only marginal benefit in elucidating the factors that support tumorigenesis. Furthermore, studies to evaluate the contribution of ECs have been obscured by the presence of stem cell-active cytokines, which can by themselves promote the survival of stem and tumor cells. In fact, it is unclear in published studies (3, 5) whether the proliferation of stem cells was mediated by elaboration of factors by ECs or exogenous factors. Therefore, the unique capacity of E4ORF1 to maintain the neoangiogenic state of PECs without the otherwise ubiquitous requirement for recombinant cytokines and serum provides for a radically different platform to identify the factors that promote the growth of stem and tumor cells. In addition, the introduction of E4ORF1 allows for purification of organ-specific ECs. These findings enable the study of the heterogeneity of ECs without compromising their neo-angiogenic integrity.
The maintenance of angiogenesis without oncogenic transformation is a feature of the E4ORF1 gene product that is uniquely conferred to human ECs. Although unstimulated E4ORF1 ϩ ECs can survive for days, upon stimulation with VEGF-A and/or FGF-2, E4ORF1 ϩ ECs proliferate in a contact-inhibited manner. The prosurvival effect of E4ORF1 was mediated through activation of the PI3K-Akt signaling pathway. Inhibition of both mTOR and NF-B signaling was essential to completely abrogate the prosurvival effect afforded by the E4ORF1 gene. These results suggest that the E4ORF1 protein augments the survival of PECs primarily by recruiting the PI3-kinase-Akt/mTOR and PI3-kinase-Akt/ NF-B pathways without oncogenic transformation. The mechanism by which E4ORF1 sustains tonic activation of the PI3-kinase-Akt pathway remains unknown and may involve interaction with as yet unrecognized signaling chaperones. Studies from murine cells transduced with E4ORF1 suggest that E4ORF1 protein might tonically activate PI3-kinase through interaction with membrane-associated PDZ proteins, including MUPP1 and ZO-2 (9). It remains to be investigated whether E4ORF1 induces Akt activation in PECs through interaction with PDZ proteins.
E4ORF1 activation of the FGF-2/FGF-R1 pathway may also contribute to the survival of PECs. Anti-FGF-R1 mAb was effective in blocking (exogenous) FGF-2-driven proliferation of E4ORF1 ϩ ECs. However, anti-FGF-R1 antibody failed to significantly block survival of unstimulated E4ORF1 ϩ cells. Thus, the effect of E4ORF1 on the angiogenic process may result from an increase in endogenous FGF-2 expression, activating an autocrine positive feedback loop. Nonetheless, only partial inhibition of E4ORF1-mediated survival of PECs was seen with either knockdown of FGF-2 expression or mAb to the extracellular domain of FGF-R1. These data suggest that FGF-2/FGF-R1 activation plays only a partial role in supporting the survival of E4ORF1 ϩ ECs and that other angiogenic pathways might synergize with FGF-2 in supporting the survival of E4ORF1 ϩ cells.
In summary, the E4ORF1 Ad gene product, through chronic activation of the PI3-kinase-Akt/mTOR/NF-B pathways, enhances survival and maintains the angiogenic repertoire in PECs without cellular transformation even in the absence of growth factors and serum. Further studies are needed to identify the specific proangiogenic factors that interact with the E4ORF1 gene product. E4ORF1 ϩ ECs will increase our understanding of the mechanism by which vascular cells regulate homeostasis of normal and cancer stem cells, thereby opening up new avenues of research into the mechanisms of organogenesis and tumorigenesis.
Materials and Methods
Isolation of PECs from Various Tissues. HUVECs and BM ECs were isolated as described (11) and cultured in EC growth medium (M199, 10% FBS, 20 g/ml EC growth supplement, and 20 units/mL heparin). Human dermal lymphatic ECs were obtained from Cambrex. Human testicular tissue, cord blood, and BM were obtained through Institutional Review Board-approved protocols and digested enzymatically, and PECs were prepared as described in the SI (12) .
Once PECs were transduced with E4ORF1 gene they were then cultured in serum/cytokine-free X-Vivo 20 or EC medium for routine expansion. All experiments described herein were performed with HUVEC-derived E4ORF1 ϩ ECs, except as specifically noted.
Construction of Ad Vectors. The Ad vectors used in this study were: (i) AdE4137 vector (serotype 5), which expresses the gene products of E4ORF1 to E4ORF6, and E4ORF6/7 but has deletions of the E3 and E1 gene complexes with no transgene in the expression cassette; (ii) AdE4ORF6, which expresses only E4ORF6 and has deletions of E4ORFs 1,2,3,3/4,7; (iii) AdE4ORF1 (H5 dl1004), which expresses only E4ORF1 and has deletions of E4ORFs 2,3,4,5,6/7; (iv) AdE4ORF3,4,3/4,6,6/7 (H5 dl1004), which expresses E4ORFs 3,4,3/4,6,6/7 but has deletions of E4ORF1 and E4ORF2; (v) AdE4ORF4, which expresses only E4ORF4 and has deletions of all other E4ORFs; and (vi) AdE4 Null , which lacks the expression of all E4ORFs. The AdE4ORF4, AdE4ORF3,4,3/4,6,6/7, and AdE4ORF1 virus vectors were propagated on W162, a Vero-derived, E4-complementing cell line. AdE4137, AdE4 Null , and AdE4ORF6 were amplified in 293 cells and purified by cesium chloride centrifugation and dialysis. All Ad vectors had a particle/pfu ratio of 100.
Generation of Lentivirus. The Ad E4ORF1 gene (serotype 5) was cloned into the pCCL-PGK lentivirus vector. Lentiviruses were generated by cotransfecting 15 g of lentiviral vector, 3 g of pENV/VSV-G, 5 g of pRRE, and 2.5 g of pRSV-REV in 293T cells (passage 8 -10; subconfluent) by the calcium precipitation method. Supernatants were collected 40 and 64 h after transfection.
siRNA Preparation and Transfection. The siRNAs for E4ORF1 (target sequence, 5Ј-GAAUCAACCUGAUGUGUUU-dTdT-3Ј), E4ORF6 (target sequence, 5Ј-GC-CAAACGCUCAUCAGUGAUA dTdT-3Ј), and FGF-2 (target sequence, 5Ј-ACCCU-CACAUCAAGCUACAACUUC A) were designed and synthesized by Invitrogen (Stealth RNAi). Twenty nanomoles of the indicated siRNA preparations control siRNA (scrambled sequence and GFP) was transfected individually into PECs by using Lipofectamine 2000. The transfection efficiency of each duplex siRNA (Ϸ80%) was confirmed by using Block-iT Fluorescent Oligo (Invitrogen).
Cell Survival Assay for PECs Treated with Antisurvival Factors. The MTT-based alamarBlue (Invitrogen) reagent was used to assess cell survival. E4ORF1 ϩ ECs were plated at a density of 1.5 ϫ 10 4 cells per well on gelatin-coated 96-well plates and incubated in growth medium overnight. Cells were treated with PI3-kinase inhibitor, wortmannin (1 M), mTOR inhibitor rapamycin (8 nM), or NK-B inhibitor CAPE (2 M) in serum/cytokine-free M199 for 5 days. For the FGF-R1 blocking experiments, E4ORF1 ϩ ECs were treated with 10 g/ml of FGF-R1 blocking mAb (clone H7; Imclone Systems) or 10 g/ml rabbit-IgG in serum/cytokinefree M199 with or without 10 ng/ml FGF-2 and heparin for 5 days. At the day 5, medium was changed to M199 containing alamarBlue reagent, and the fluorescence (Ex530/Em590) was measured after 3 more 1-h incubations.
Western Blot Analysis. Cells were lysed in RIPA buffer and immunoblotted with antibodies to Ser-473-phospho-Akt, total Akt, FGF-2, and ␤-actin. For measurement of pMAPK, E4ORF1 Ϫ ECs and E4ORF1 ϩ ECs were serum-starved for 6 h and 3 days, respectively, followed by stimulation with 50 ng/ml of VEGF-A for 10 min. pMAPK was detected with polyclonal rabbit anti-pMAPK p44/42 antibody (9101; Cell Signaling). Signal was developed with a ECL Chemiluminescence Kit.
Determination of Contribution of E4ORF1 ؉ ECs to Angiogenesis in Vivo and in
Vitro. E4ORF1 ϩ ECs were inoculated with Matrigel and/or HL60 leukemic cells. For assessment of angiogenesis in vivo E4ORF1 ؉ ECs and E4ORF1 Ϫ ECs (5 ϫ 10 6 cells) were mixed with Matrigel and implanted in the flanks of 2 groups of mice (Fig.  4) . The mice were killed after indicated times and tissue was snap-frozen in OCT (Tissue-Tek). Functionality of donor derived blood vessels was assessed by perfusion labeling as detailed in the SI.
For in vitro proliferation assays human HL60 or embryonal carcinoma cells (NCCIT) from ATCC were cocultured in the presence or absence of E4ORF1 ϩ ECs in serum/cytokine-free conditions either in direct cellular contact with E4ORF1 ϩ ECs or the upper chambers of Transwells (0.4-m pore size) physically separated from the E4ORF1 ϩ ECs, which were plated in the lower chamber of the plates. Subsequently, the number of proliferating cancer cells was determined by trypan blue exclusion.
Immunostaining. Rabbit polyclonal anti-human FGF-2 and phospho-Akt (Santa Cruz Biotechnology), goat polyclonal anti-human VE-cadherin l (R&D), MECA-32 rat anti-mouse endothelial (BD Pharmingen), mouse anti-human CD34, antihuman CD31, and rabbit anti-human VWF (Dako) antibodies were used for confirmation of PEC identity by immunostaining. Fig. S1 . Characterization of the outgrown testicular E4ORF1 ϩ ECs. Testicular tissue was enzymatically dissociated, transduced at passage zero with E4ORF1, and serially passaged and expanded by using standard EC growth medium. Homogeneous cells with endothelial morphology were stained (green) with antibodies against endothelial antigens, including von Willebrand factor (A), VE-cadherin (B), CD34 (C), and CD31 (D), and analyzed by confocal microscopy, confirming the endothelial identity of the cultures. Prodium iodide (red) was used as a nuclear counterstain. (Magnifications: 20ϫ objective.) Fig. S2 . Effect of small-molecule inhibitors on E4ORF1-expressing PECs. Lenti-E4ORF1 infected-PECs (derived from HUVECs) were treated with 10 M SU5402 (an FGFR inhibitor) or 10 M SU5416 (a VEGFR2 inhibitor) for 48 h in serum/cytokine-free or FGF-2-supplemented medium, and the number of viable cells was quantified. To determine whether certain genes were present in both E4ORF1 ϩ and E4ORF Ϫ (HUVEC) populations, microarray analyses were performed by entering RMA-normalized data into the Genespring program for data visualization, expression level determination, data filtering, and examination of overlap in the expression profiles of proangiogenic genes. Proangiogenic genes that have been published to be present in the control HUVECs were identified and if after normalization to the median they were considered to be expressed or present in both E4ORF1 ϩ and E4ORF1 Ϫ cells, they were then selected for display.
